NASDAQ: MIST

Milestone Pharmaceuticals Inc.

Healthcare | Biotechnology

No licensed closing price on file for MIST. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 12:39 UTC.

What Milestone Pharmaceuticals Inc. does

The company is a biopharmaceutical firm developing cardiovascular medicines, with its first approved product being CARDAMYST (etripamil) nasal spray for treating acute episodes of paroxysmal supraventricular tachycardia in adults. CARDAMYST is a self-administered treatment that works by blocking calcium channels in the heart and is designed to act rapidly through nasal absorption. The company manufactures CARDAMYST through a global supply chain and distributes it via wholesalers to retail pharmacies.

Summarized from Milestone Pharmaceuticals Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for MIST are available in Oxford Ledge.
Open MIST in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-12

Most recent filed transactions — June 2026:

2026-06-12DirectorStock Option (right to buy)Award77,000—
2026-06-12DirectorStock Option (right to buy)Award77,000—
2026-06-12DirectorStock Option (right to buy)Award77,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Pavaki Capital Management LLC9,067,848$12.15M+0.1%
RTW INVESTMENTS, LP7,833,336$10.50M+23.7%
Propel Bio Management, LLC7,429,590$9.96M+80.4%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2023-03-27Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-12-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2020-06-09Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
globenewswire.com2026-09-03POS
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
seekingalpha.com2026-08-18NEG
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
Seeking Alpha Feed2026-08-18NEG
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
seekingalpha.com2026-08-12

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MIST and 5,000+ tickers.

Create a free account — keep MIST

For your agent

GET /api/data?ticker=MIST

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt